Significance of the pulmonary function test for the diagnosis of subglottic stenosis: a systematic review

B-ENT ◽  
2021 ◽  
Vol 16 (4) ◽  
pp. 233-239
Author(s):  
Abdulaziz Alrabiah ◽  
◽  
Mohammed Jomah ◽  
Shatha Alduraywish ◽  
Shaffi Shaikh ◽  
...  
Keyword(s):  
Systematic Review ◽  
Pulmonary Function ◽  
Pulmonary Function Test ◽  
Subglottic Stenosis ◽  
Function Test

scholarly journals Radiological and functional lung sequelae of COVID-19: a systematic review and meta-analysis

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Matsuo So ◽  
Hiroki Kabata ◽  
Koichi Fukunaga ◽  
Hisato Takagi ◽  
Toshiki Kuno
Keyword(s):  
Systematic Review ◽  
Pulmonary Function ◽  
Hospital Discharge ◽  
Pulmonary Function Test ◽  
Wide Spectrum ◽  
Meta Analysis ◽  
Ground Glass Opacity ◽  
Chest Ct ◽  
Function Test

Abstract Background The coronavirus disease 2019 (COVID-19) causes a wide spectrum of lung manifestations ranging from mild asymptomatic disease to severe respiratory failure. We aimed to clarify the characteristics of radiological and functional lung sequelae of COVID-19 patients described in follow-up period. Method PubMed and EMBASE were searched on January 20th, 2021 to investigate characteristics of lung sequelae in COVID-19 patients. Chest computed tomography (CT) and pulmonary function test (PFT) data were collected and analyzed using one-group meta-analysis. Results Our search identified 15 eligible studies with follow-up period in a range of 1–6 months. A total of 3066 discharged patients were included in these studies. Among them, 1232 and 1359 patients were evaluated by chest CT and PFT, respectively. The approximate follow-up timing on average was 90 days after either symptom onset or hospital discharge. The frequency of residual CT abnormalities after hospital discharge was 55.7% (95% confidential interval (CI) 41.2–70.1, I2 = 96.2%). The most frequent chest CT abnormality was ground glass opacity in 44.1% (95% CI 30.5–57.8, I2 = 96.2%), followed by parenchymal band or fibrous stripe in 33.9% (95% CI 18.4–49.4, I2 = 95.0%). The frequency of abnormal pulmonary function test was 44.3% (95% CI 32.2–56.4, I2 = 82.1%), and impaired diffusion capacity was the most frequently observed finding in 34.8% (95% CI 25.8–43.8, I2 = 91.5%). Restrictive and obstructive patterns were observed in 16.4% (95% CI 8.9–23.9, I2 = 89.8%) and 7.7% (95% CI 4.2–11.2, I2 = 62.0%), respectively. Conclusions This systematic review suggested that about half of the patients with COVID-19 still had residual abnormalities on chest CT and PFT at about 3 months. Further studies with longer follow-up term are warranted.

scholarly journals Magnesium Administration For COPD Exacerbation: A Systematic Review and Meta-analysis

2021 ◽  
Vol 1 (3) ◽  
pp. 38-46
Author(s):  
Hala Alzaid ◽  
Fay Aldossari ◽  
Sharafaldeen Bin Nafisah
Keyword(s):  
Systematic Review ◽  
Pulmonary Function ◽  
Risk Ratio ◽  
Pulmonary Function Test ◽  
Magnesium Sulphate ◽  
Meta Analysis ◽  
World Health ◽  
Copd Exacerbation ◽  
Function Test ◽  
The Mean

BACKGROUND The role of magnesium in patients with acute chronic obstructive pulmonary disease (COPD) exacerbation remains to be determined. AIM We aim to explore the effect of magnesium on COPD exacerbation, as well as its impact on pulmonary function tests and on hospital admissions for acute exacerbation in the emergency department. METHODS This is a systematic review and meta-analysis that included a search of the keywords "magnesium" and "COPD" on PubMed, Google Scholar, Cochrane databases, and Gray literature (ClinicalTrials.gov and World Health Organization International Clinical Trials Registry Platform) from 1963 to May 2021. RESULTS The use of IV magnesium reduced the risk ratio for admission RR= 0.85 (95% CI 0.62 to 1.17). The combined risk ratio for admission increased to 0.95 when we added nebulised magnesium sulphate (95% CI 0.85 to 1.07), p>0.05. The mean score for improvement after IV magnesium was higher (M=16.75, SD=5.11) than the mean score before its administration (M=8.74, SD=8.85), t(4)=-2.57, p=0.031. Thus, the use of IV magnesium sulphate results in a 91.64% improvement in the pulmonary function test. CONCLUSION IV magnesium sulphate improves the pulmonary function test of patients with acute COPD exacerbation in the ED, and possibly reduces the admission rate.

Air Trapping on HRCT in Asthmatics: Correlation with Pulmonary Function Test

1997 ◽  
Vol 36 (2) ◽  
pp. 235
Author(s):  
Jung Hwa Hwang ◽  
Chull Hee Cha ◽  
Jai Soung Park ◽  
Young Beom Kim ◽  
Hae Kyung Lee ◽  
...  
Keyword(s):  
Pulmonary Function ◽  
Pulmonary Function Test ◽  
Air Trapping ◽  
Function Test

Pulmonary function test in Petrol Pump workers of Ahmedabad

2012 ◽  
Vol 2 (7) ◽  
pp. 380-381
Author(s):  
Dr. Rajula Tyagi ◽  
◽  
Dr.Devanshi U Dr.Devanshi U
Keyword(s):  
Pulmonary Function ◽  
Pulmonary Function Test ◽  
Function Test ◽  
Petrol Pump

scholarly journals Pulmonary function test values due to a diaphragmatic hernia

2016 ◽  
pp. bcr2016216542
Author(s):  
Jesper Rømhild Davidsen ◽  
Leo Nygaard ◽  
Christian B Laursen ◽  
Daniel Pilsgaard Henriksen
Keyword(s):  
Pulmonary Function ◽  
Diaphragmatic Hernia ◽  
Pulmonary Function Test ◽  
Function Test

P05.05 Impact of Lung Stereotactic Body Radiotherapy on Pulmonary Function Test – Experience from Tertiary Cancer Centre in India

2021 ◽  
Vol 16 (10) ◽  
pp. S983
Author(s):  
P. Sawant ◽  
P. Mittal ◽  
A. Tibdewal ◽  
N. Mummudi ◽  
S. Tandon ◽  
...  
Keyword(s):  
Pulmonary Function ◽  
Pulmonary Function Test ◽  
Stereotactic Body Radiotherapy ◽  
Cancer Centre ◽  
Function Test
Sign in / Sign up

Export Citation Format

Share Document